View Item 

Show simple item record

Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States
dc.contributor.authorLi, Ang
dc.contributor.authorCarlson, Josh J.
dc.contributor.authorKuderer, Nicole M.
dc.contributor.authorSchaefer, Jordan K.
dc.contributor.authorLi, Shan
dc.contributor.authorGarcia, David A.
dc.contributor.authorKhorana, Alok A.
dc.contributor.authorCarrier, Marc
dc.contributor.authorLyman, Gary H.
dc.date.accessioned2020-04-02T18:38:09Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-04-02T18:38:09Z
dc.date.issued2020-04-15
dc.identifier.citationLi, Ang; Carlson, Josh J.; Kuderer, Nicole M.; Schaefer, Jordan K.; Li, Shan; Garcia, David A.; Khorana, Alok A.; Carrier, Marc; Lyman, Gary H. (2020). "Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States." Cancer (8): 1736-1748.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/154607
dc.publisherWiley Periodicals, Inc.
dc.publisherNational Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch
dc.subject.othervenous thromboembolism
dc.subject.otherneoplasm
dc.subject.otherfactor Xa inhibitors
dc.subject.othercost‐benefit analysis
dc.subject.otherapixaban
dc.subject.otherrivaroxaban
dc.titleCost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154607/1/cncr32724.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154607/2/cncr32724_am.pdf
dc.identifier.doi10.1002/cncr.32724
dc.identifier.sourceCancer
dc.identifier.citedreferenceKwon JS, Sun CC, Peterson SK, et al. Cost‐effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer. 2008; 113: 326 ‐ 335. doi: 10.1002/cncr.23554
dc.identifier.citedreferenceRaskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer‐associated venous thromboembolism. N Engl J Med. 2018; 378: 615 ‐ 624. doi: 10.1056/NEJMoa1711948
dc.identifier.citedreferenceChew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166: 458 ‐ 464. doi: 10.1001/.458
dc.identifier.citedreferenceMartinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population‐based cohort study in patients without active cancer. Thromb Haemost. 2014; 112: 255 ‐ 263. doi: 10.1160/TH13-09-0793
dc.identifier.citedreferenceCohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population‐based cohort study. Thromb Haemost. 2017; 117: 57 ‐ 65. doi: 10.1160/TH15-08-0686
dc.identifier.citedreferenceEnde‐Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017; 49: 880 ‐ 888. doi: 10.1183/13993003.01792-2016
dc.identifier.citedreferenceKahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post‐thrombotic syndrome: a randomised placebo‐controlled trial. Lancet. 2014; 383: 880 ‐ 888. doi: 10.1016/S0140-6736(13)61902-9
dc.identifier.citedreferenceSurveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database. Incidence‐SEER 18 Registries Research Data + Hurricane Katrina Impacted Louisiana Cases, November 2018 Submission (2000‐2016). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2019.
dc.identifier.citedreferenceArias E, Xu J, Kochanek KD. United States Life Tables, 2016. Natl Vital Stat Rep. 2019; 68: 1 ‐ 66. doi: 10.4135/9781412952484.n432
dc.identifier.citedreferenceRed Book. Average Wholesale Price (AWP). Truven Health Analytics; 2019. Accessed June 24, 2019. http://truvenhealth.com/Products/Micromedex/Product-Suites/Clinical-Knowledge/RED-BOOK
dc.identifier.citedreferencePreblick R, Kwong WJ, White RH, Goldhaber SZ. Cost‐effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai‐VTE study. Hosp Pract (1995). 2015; 43: 249 ‐ 257. doi: 10.1080/21548331.2015.1099412
dc.identifier.citedreferenceLee WC, Christensen MC, Joshi AV, Pashos CL. Long‐term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis. 2007; 23: 57 ‐ 65. doi: 10.1159/000096542
dc.identifier.citedreferenceCaprini JA, Botteman MF, Stephens JM, et al. Economic burden of long‐term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health. 2003; 6: 59 ‐ 74. doi: 10.1046/j.1524-4733.2003.00204.x
dc.identifier.citedreferenceKirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy. 2011; 9: 293 ‐ 303. doi: 10.2165/11592430-000000000-00000
dc.identifier.citedreferenceConsumer Price Index. All Urban Consumers, Medical Care‐Not Seasonally Adjusted. US Department of Labor, Bureau of Labor Statistics; 2018. Accessed June 24, 2019. http://data.bls.gov/cgi-bin/surveymost?cu
dc.identifier.citedreferenceRomanus D, Kindler HL, Archer L, et al. Does health‐related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia Group B (CALGB 80303). J Pain Symptom Manage. 2012; 43: 205 ‐ 217. doi: 10.1016/j.jpainsymman.2011.09.001
dc.identifier.citedreferenceCurran D, Pozzo C, Zaluski J, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5‐fluorouracil and folinic acid: results of a randomised phase III trial. Qual Life Res. 2009; 18: 853 ‐ 861. doi: 10.1007/s11136-009-9493-z
dc.identifier.citedreferencePapaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first‐line treatment of stage III‐IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technol Assess. 2012; 16: 1 ‐ 253, iii‐iv. doi: 10.3310/hta16370
dc.identifier.citedreferenceSchunemann HJ, Ventresca M, Crowther M, et al. Use of heparins in patients with cancer: individual participant data metaanalysis of randomised trials study protocol. BMJ Open. 2016; 6: e010569. doi: 10.1136/bmjopen-2015-010569
dc.identifier.citedreferenceHogg K, Kimpton M, Carrier M, Coyle D, Forgie M, Wells P. Estimating quality of life in acute venous thrombosis. JAMA Intern Med. 2013; 173: 1067 ‐ 1072. doi: 10.1001/jamainternmed.2013.563
dc.identifier.citedreferenceLenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997; 4: 49 ‐ 56. doi: 10.1136/jamia.1997.0040049
dc.identifier.citedreferenceGhofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369: 319 ‐ 329. doi: 10.1056/NEJMoa1209657
dc.identifier.citedreferenceHusereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013; 16: 231 ‐ 250. doi: 10.1016/j.jval.2013.02.002
dc.identifier.citedreferenceNeumann PJ, Cohen JT, Weinstein MC. Updating cost‐effectiveness—the curious resilience of the $50,000‐per‐QALY threshold. N Engl J Med. 2014; 371: 796 ‐ 797. doi: 10.1056/NEJMp1405158
dc.identifier.citedreferenceConnors JM. Prophylaxis against venous thromboembolism in ambulatory patients with cancer. N Engl J Med. 2014; 370: 2515 ‐ 2519. doi: 10.1056/nejmra1401468
dc.identifier.citedreferenceAgnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012; 366: 601 ‐ 609. doi: 10.1056/NEJMoa1108898
dc.identifier.citedreferenceAgnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo‐controlled, double‐blind study. Lancet Oncol. 2009; 10: 943 ‐ 949. doi: 10.1016/S1470-2045(09)70232-3
dc.identifier.citedreferenceBlom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293: 715 ‐ 722. doi: 10.1001/jama.293.6.715
dc.identifier.citedreferencePDQ Adult Treatment Editorial Board. Financial Toxicity and Cancer Treatment (PDQ): Health Professional Version. National Cancer Institute; 2002.
dc.identifier.citedreferenceSculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial‐based economic evaluation for health care decision making? Health Econ. 2006; 15: 677 ‐ 687. doi: 10.1002/hec.1093
dc.identifier.citedreferenceKhorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5: 632 ‐ 634. doi: 10.1111/j.1538-7836.2007.02374.x
dc.identifier.citedreferenceSorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343: 1846 ‐ 1850. doi: 10.1056/NEJM200012213432504
dc.identifier.citedreferenceKhorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high‐risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res. 2013; 5: 101 ‐ 108. doi: 10.2147/CEOR.S39964
dc.identifier.citedreferenceLi A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low‐molecular‐weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta‐analysis. Thromb Res. 2019; 173: 158 ‐ 163. doi: 10.1016/j.thromres.2018.02.144
dc.identifier.citedreferenceLi A, Manohar PM, Garcia DA, Lyman GH, Steuten LM. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019; 180: 37 ‐ 42. doi: 10.1016/j.thromres.2019.05.012
dc.identifier.citedreferenceConnell NT, Connors JM. Cost‐effectiveness of edoxaban versus dalteparin for the treatment of cancer‐associated thrombosis. J Thromb Thrombolysis. 2019; 48: 382 ‐ 386. doi: 10.1007/s11239-019-01903-z
dc.identifier.citedreferenceCarrier M, Abou‐Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019; 380: 711 ‐ 719. doi: 10.1056/NEJMoa1814468
dc.identifier.citedreferenceKhorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high‐risk ambulatory patients with cancer. N Engl J Med. 2019; 380: 720 ‐ 728. doi: 10.1056/NEJMoa1814630
dc.identifier.citedreferenceAkl EA, Kahale LA, Hakoum MB, et al. Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst Rev. 2017; 9: CD006652. doi: 10.1002/14651858.CD006652.pub5
dc.identifier.citedreferenceDi Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016; 12: CD008500. doi: 10.1002/14651858.CD008500.pub4
dc.identifier.citedreferenceKhorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy‐associated thrombosis. Blood. 2008; 111: 4902 ‐ 4907. doi: 10.1182/blood-2007-10-116327
dc.identifier.citedreferenceFederal Reserve. Discount Window. Published 2018. Accessed June 24, 2019. https://www.frbdiscountwindow.org
dc.identifier.citedreferenceLi A, Kuderer NM, Garcia DA, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta‐analysis. J Thromb Haemost. 2019; 17: 2141 ‐ 2151. doi: 10.1111/jth.14613
dc.identifier.citedreferenceDerSimonian R, Laird N. Meta‐analysis in clinical trials. Control Clin Trials. 1986; 7: 177 ‐ 188. doi: 10.1016/0197-2456(86)90046-2
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32724.pdf
Size:
619.2KB
Format:
PDF
View/Open
Name:
cncr32724_am.pdf
Size:
490.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.